Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Single-Cell Analysis of Immune Recognition in Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitor Discontinuation

Blood (2023) 142 (Supplement 1): 3146.

https://doi.org/10.1182/blood-2023-185630

Published: 2023

Journal Articles

FINAL Analysis of a PAN European STOP Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI Study

Blood (2021) 138 (Supplement 1): 633.

https://doi.org/10.1182/blood-2021-148369

Published: 2021

Journal Articles

Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial

Carlo Gambacorti-Passerini, Tim H Brümmendorf, Elisabetta Abruzzese, Kevin R. Kelly, Vivian G. Oehler, Valentín Garcia-Gutiérrez, Henrik Hjorth-Hansen, Thomas Ernst, Eric Leip, Simon Purcell, Gerald Luscan, Andrea Viqueira, Frank Giles, Andreas Hochhaus

Blood (2021) 138 (Supplement 1): 1475.

https://doi.org/10.1182/blood-2021-150352

Published: 2021

Journal Articles

Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial

Jorge E. Cortes, MD, Philipp D le Coutre, MD, Carlo Gambacorti-Passerini, MD, Henrik Hjorth-Hansen, MD, Pia Raanani, MD, Valentín Garcia-Gutiérrez, MD PhD, Vamsi Kota, MD, Simon Purcell, Andrea Viqueira, Eric Leip, Tim H Brümmendorf, MD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-134912

Published: 2020

Journal Articles

Single-Cell Roadmap of Immune Cell Response in Chronic Myeloid Leukemia

Jani Huuhtanen, Jason Theodoropoulos, BSc, Rebecca Warfvinge, MSc, Andreas Burchert, MD, Tiina Kasanen, Jay Klievink, MSc, Shady Adnan Awad, MD, Olli Dufva, MD, Mette Ilander, PhD, Taina Jaatinen, Ulla Olsson-Strömberg, MD PhD, Henrik Hjorth-Hansen, MD, Göran Karlsson, PhD, Harri Lähdesmäki, PhD, Anna Kreutzman, PhD, Satu Mustjoki, MD PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-139134

Published: 2020

Journal Articles

Cold agglutinin disease revisited: a multinational, observational study of 232 patients

Blood (2020) 136 (4): 480–488.

https://doi.org/10.1182/blood.2020005674

Published: 2020

Includes: Supplemental data

Journal Articles

Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1647.

https://doi.org/10.1182/blood-2019-129710

Published: 2019

Journal Articles

Health-Related Quality of Life Outcomes in Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Dasatinib and Low Dose Pegylated Interferon

Henrik Hjorth-Hansen, MD, Satu Mustjoki, MD PhD, Ulla Olsson-Strömberg, MD PhD, Jesper Stentoft, Professor, dr.MD, Fabio Efficace, PhD, Hemming Johansson, PhD, Yvonne Brandberg, PhD

Blood (2018) 132 (Supplement 1): 4260.

https://doi.org/10.1182/blood-2018-99-111714

Published: 2018

Journal Articles

Plasma Fms-Related Tyrosine Kinase 3 Ligand (Flt3L) Levels at Diagnosis Correlate with Treatment Response in Chronic Myeloid Leukemia

Bhagwan Yadav, PhD, Mette Ilander, PhD, Anna Kreutzman, PhD, Henrik Hjorth-Hansen, MD, Satu Mustjoki, MDPhD

Blood (2017) 130 (Supplement 1): 1602.

https://doi.org/10.1182/blood.V130.Suppl_1.1602.1602

Published: 2017

Journal Articles

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Susanne Saussele, MD, Johan Richter, MD PhD, Joelle Guilhot, PhD, Henrik Hjorth-Hansen, MD, Antonio Medina de Almeida, MD PhD, Jeroen J. W. M. Janssen, MD, Jiri Mayer, Prof, MD SCs, Perttu Koskenvesa, MD, Panayiotis Panayiotidis, MD PhD, Ulla Olsson-Strömberg, MD PhD, Juan Luis Steegmann, MD PhD, Hanne Vestergaard, MD, Hans Ehrencrona, MD PhD, Veli Kairisto, Kateřina Machová Poláková, PhD, Martin Müller, MD, Satu Mustjoki, MDPhD, Marc G. Berger, MD PhD, Philippe Rousselot, Martine Escoffre-Barbe, MD, Gabriel Etienne, MD PhD, Jolanta Dengler, MD, Françoise Rigal-Huguet, MD, Nikolas von Bubnoff, MD, Hana Klamova, MD, Edgar Faber, MD, François Guilhot, MD, Kourosh Lotfi, MD, Delphine Rea, MD, Tim H. Brümmendorf, MD, Gorgine de Greef, MD, Leif Stenke, MD, Franck Emmanuel Nicolini, MD PhD, Laurence Legros, MD PhD, Andreas Burchert, MD, Jaroslava Voglová, MD, Aude Charbonnier, MD, Emmanuel Gyan, MDPhD, Maria-Elisabeth Goebeler, MD, Peter E. Westerweel, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 313.

https://doi.org/10.1182/blood.V130.Suppl_1.313.313

Published: 2017

Journal Articles

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

Rebecca Warfvinge, Linda Geironson, Mikael N. E. Sommarin, Stefan Lang, Christine Karlsson, Teona Roschupkina, Leif Stenke, Jesper Stentoft, Ulla Olsson-Strömberg, Henrik Hjorth-Hansen, Satu Mustjoki, Shamit Soneji, Johan Richter, Göran Karlsson

Blood (2017) 129 (17): 2384–2394.

https://doi.org/10.1182/blood-2016-07-728873

Published: 2017

Includes: Supplemental data

Journal Articles

Telomere Length Shortening in the CML Leukemic Stem Cell Compartment Correlates with the Respective Clone Size: Evidence for Early Vs. Late Chronic Phase

Anne-Sophie Bouillon, Monica S. Ferreira, PhD, Shady Adnan Awad, Johan Richter, MD, Henrik Hjorth-Hansen, MD PhD, Thoas Fioretos, Sebastian Hummel, Mirle Schemionek, PhD, Satu Mustjoki, MD PhD, Fabian Beier, MD, Tim H. Brümmendorf, MD

Blood (2016) 128 (22): 4243.

https://doi.org/10.1182/blood.V128.22.4243.4243

Published: 2016

Journal Articles

Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial

Blood (2016) 128 (22): 787.

https://doi.org/10.1182/blood.V128.22.787.787

Published: 2016

Journal Articles

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

Blood (2016) 128 (22): 789.

https://doi.org/10.1182/blood.V128.22.789.789

Published: 2016

Journal Articles

Immunological Monitoring of CML Patients during First-Line Bosutinib and Imatinib Treatment

Anna Kreutzman, PhD, Perttu Koskenvesa, MD, Kasanen Tiina, Ulla Olsson-Strömberg, MD PhD, Jesper Stentoft, MD PhD, Leif Stenke, MD PhD, Lene Udby, MD, Bjorn T. Gjertsen, MD PhD, Kourosh Lotfi, MD, Berit Markevän, MD PhD, Jeroen Janssen, MD, Tim Brümmendorf, MD, Johan Richter, MD, Henrik Hjorth-Hansen, MD PhD, Satu Mustjoki, MD PhD

Blood (2016) 128 (22): 3069.

https://doi.org/10.1182/blood.V128.22.3069.3069

Published: 2016

Journal Articles

Effects of Dasatinib and Interferon-α Combination Treatment on the Immune System in CML

Blood (2016) 128 (22): 627.

https://doi.org/10.1182/blood.V128.22.627.627

Published: 2016

Journal Articles

Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients

Henrik Hjorth-Hansen, MD PhD, Jesper Stentoft, Johan Richter, MD PhD, Perttu Koskenvesa, MD, Arta Dreimane, MD, Kimmo Porkka, MD PhD, Tobias Gedde-Dahl, MDPhD, Bjorn Gjertsen, MD PhD, Franz X. Gruber, MDPhD, Martin Hoglund, MD PhD, Anna Lubking, MD, Kristina Myhr-Eriksson, MD, Berit Markevärn, Hanne Vestergaard, MDPhD, Ole Weis Bjerrum, MDPhD, Leif Stenke, MDPhD, Satu Mustjoki, MD PhD, Ulla Stromberg, MDPhD

Blood (2015) 126 (23): 477.

https://doi.org/10.1182/blood.V126.23.477.477

Published: 2015

Journal Articles

Mature, Adaptive-like CD56 DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Blood (2015) 126 (23): 343.

https://doi.org/10.1182/blood.V126.23.343.343

Published: 2015

Journal Articles

Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study

Blood (2015) 126 (23): 4022.

https://doi.org/10.1182/blood.V126.23.4022.4022

Published: 2015

Journal Articles

Bone Marrow Lymphocytic Status during Tyrosine Kinase Inhibitor Therapy and Its Relation to Therapy Response in Chronic Phase Chronic Myeloid Leukemia Patients

Mohamed El Missiry, MD MSc, Shady Adnan, MD MSc, Hanna Rajala, MD PhD, Ahmed Al-Samadi, DDS, PhD, Marja Ekblom, Berit Markevän, MD PhD, Ingbritt Åstrand-Grundström, Maren Wold, Birgitte Ravn Juhl, MD dr.MDsci, Ole Weis Bjerrum, MD DMSc, Inger Haulin, Kimmo Porkka, MD PhD, Ulla Olsson-Strömberg, Henrik Hjorth-Hansen, MD PhD, Satu Mustjoki, MD PhD

Blood (2015) 126 (23): 4027.

https://doi.org/10.1182/blood.V126.23.4027.4027

Published: 2015

NARROW

Single-Cell Analysis of Immune Recognition in Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitor Discontinuation

FINAL Analysis of a PAN European STOP Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI Study

Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial

Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial

Single-Cell Roadmap of Immune Cell Response in Chronic Myeloid Leukemia

Cold agglutinin disease revisited: a multinational, observational study of 232 patients

Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia

Health-Related Quality of Life Outcomes in Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Dasatinib and Low Dose Pegylated Interferon

Plasma Fms-Related Tyrosine Kinase 3 Ligand (Flt3L) Levels at Diagnosis Correlate with Treatment Response in Chronic Myeloid Leukemia

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

Telomere Length Shortening in the CML Leukemic Stem Cell Compartment Correlates with the Respective Clone Size: Evidence for Early Vs. Late Chronic Phase

Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

Immunological Monitoring of CML Patients during First-Line Bosutinib and Imatinib Treatment

Effects of Dasatinib and Interferon-α Combination Treatment on the Immune System in CML

Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients

Mature, Adaptive-like CD56 DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study

Bone Marrow Lymphocytic Status during Tyrosine Kinase Inhibitor Therapy and Its Relation to Therapy Response in Chronic Phase Chronic Myeloid Leukemia Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only